DCPrime

About:

DCPrime is a clinical stage company which develops novel cancer immunotherapies based on its DCOne platform technology.

Top Investors: SkylineDx, Horizon 2020, Thuja Capital, Van Herk Ventures

Description:

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

Total Funding Amount:

22.2M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Leiden, Zuid-Holland, The Netherlands

Founded Date:

2006-01-01

Contact Email:

info(AT)dcprime.nl

Founders:

Ada Kruisbeek

Number of Employees:

11-50

Last Funding Date:

2018-03-26

IPO Status:

Private

Industries: